



PRESS RELEASE

Crucell Confirms Delisting of Berna Biotech

Leiden, The Netherlands, September 8, 2006 – Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) announced today that the delisting of Berna Biotech (Swiss Exchange: BBIN), the Swiss company acquired by Crucell in February 2006, has been approved by the SWX Swiss Exchange. The delisting has been set for September 18, 2006, with the last trading day on the SWX Swiss Exchange being September 15, 2006.

Approval of the delisting follows the relevant Bern-Laupen district court's approval of the squeeze-out of all publicly-held registered shares of Berna Biotech. With reference to the public exchange offer of Crucell dated December 15, 2005, the owners of the squeezed out shares will receive compensation corresponding to the exchange offer. As such, for each registered share of Berna Biotech, 0.447 newly issued and fully paid common shares of Crucell, with a nominal value of € 0.24, will be delivered. Any fractional entitlements will be paid out in cash in CHF, whereas one common share of Crucell corresponds to CHF 32.66. Crucell will bear the Swiss stamp duty imposed on the compensation.

About Crucell

Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, including both early-stage products and products almost ready to go to market. Several Crucell products are based on its unique PER.C6® production technology. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, GSK and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, Spain, Italy and Korea. The Company employs about 900 people. For more information, please visit www.crucell.com.

Forward-looking statements

This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on July 6, 2006, and the section entitled "Risk Factors". The Company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP) and Europe (IFRS).



For further information please contact:

Crucell N.V.

Paul Vermeij

Director Investor Relations and
Corporate Communications

Tel. +31-(0)71-524 8718

p.vermeij@crucell.com